By Connor Hart
Shares of Theratechnologies jumped after the company received Food and Drug Administration approval for Egrifta WR, its treatment for excess abdominal fat in adults with HIV and lipodystrophy.
The stock climbed 50%, to $2.32, in after-hours trading Tuesday. Shares are up 15% in the past year through the close, despite having fallen 16% in the past three months.
The Canadian biopharmaceutical company said the treatment is set to replace Egrifta SV. The new formulation is a daily injectable requiring weekly reconstitution, meaning it requires less than half the administration volume as the current formulation, which is reconstituted daily.
The treatment will be manufactured at a new U.S.-based contract drug manufacturing organization, and is set to be patent protected in the U.S. until 2033, the company said.
"We are pleased to offer this improved, more convenient version of tesamorelin for injection to help people with HIV and their healthcare providers more effectively manage comorbidities like lipodystrophy, which today often presents as central adiposity," Chief Medical Officer Christian Marsolais said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
March 25, 2025 18:16 ET (22:16 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.